Unveiling 4 Analyst Insights On Paragon 28
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Paragon 28 (NYSE:FNA), with recent evaluations showing a shift towards bullish sentiment. The average 12-month price target has increased to $17.25 from $16.00, indicating a positive outlook. Paragon 28, a medical devices company, has shown solid revenue growth but faces challenges in profitability and asset utilization. Despite a smaller market capitalization and a net margin of -32.3%, its ROE outperforms industry benchmarks.
April 04, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a mixed but increasingly bullish outlook on Paragon 28, with an average price target of $17.25 reflecting a positive sentiment. The company's solid revenue growth contrasts with its profitability and asset utilization challenges.
The increase in the average price target to $17.25 from $16.00, along with the recent bullish ratings from analysts, suggests a positive short-term outlook for FNA. However, the company's challenges in profitability and asset utilization may temper gains. The detailed analysis of Paragon 28's financials and the recent analyst ratings provide a comprehensive view, supporting the positive score but with caution due to underlying challenges.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100